The U.S. Food and Drug Administration (FDA) has suspended Novavax’s experimental combined COVID-19 and flu vaccine clinical trials. This decision followed reports of a participant’s symptoms of nervous system damage, and the stock market has reacted to these reports.
The vaccine, expected to be groundbreaking due to its simultaneous protection against COVID and flu, may face delays. Novavax disclosed that a participant in the mid-stage clinical trial experienced symptoms of motor neuropathy last month. This condition involves damage to the nerve cells responsible for muscle control and movement. However, the company emphasizes that no certainty exists that the vaccine caused these symptoms.